Business Editors
PITTSBURGH--(BUSINESS WIRE)--Feb. 16, 2001
Mylan Laboratories Inc. (NYSE:MYL) has indicated that they are presently marketing the antibiotic, Zagam(R), and it remains a part of their Bertek branded product line.
Mylan wrote down $3.6 million of the Zagam(R) product license asset in their third quarter, which was reported on January 30, 2001, because of supply issues.
Mylan continues to work to try and resolve the issues surrounding Zagam(R).
Mylan Laboratories Inc., is one of the largest manufacturers and marketers of prescription generic pharmaceuticals in the United States. Mylan also develops and markets branded pharmaceutical products through its Bertek Pharmaceuticals Inc. subsidiary.
COPYRIGHT 2001 Business Wire
COPYRIGHT 2001 Gale Group